Business Wire

NY-CLARITY-AI

17.3.2022 18:06:12 CET | Business Wire | Press release

Share
Clarity AI: Only 7% of a Sample of 31,000 Equity Funds Have More Than 10% “Green Revenues,” as Defined in the EU Taxonomy

The EU Taxonomy aims to align all market stakeholders on what is considered sustainable in the context of the EU, but investors need greater transparency on just how green the funds they are buying really are. Analysis by Clarity AI, the market-leading, global sustainability technology platform, reveals significant differences between fund revenues aligned with green – and EU Taxonomy related – objectives across different types of sustainable investment products in the market today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005718/en/

Under the Sustainability Finance Disclosure Regulation (or SFDR), investors need to report the EU Taxonomy alignment as part of the sustainability profile of funds, which need to be classified into one of three categories:

  • Article 6: non-sustainable funds
  • Article 8: funds that promote sustainable characteristics but not as an overarching objective
  • Article 9: funds that have been specifically created to address sustainability goals

In a whitepaper titled “EU Taxonomy: Using Tech to Analyze ‘Green’ Fund Performance,” Clarity AI analyzed an investable universe of 31,000 equity funds on how these products perform against new EU Taxonomy requirements and assessed the common traits across funds, which are often branded in some way as “green.” The analysis shows that:

  • Globally, 3.6% of revenues can be considered green (“green revenues”) – that is, they contribute to mitigating climate change.
  • Only 7% of the 31,000 equity funds analyzed have more than 10% green revenues, as defined in the EU taxonomy.1
  • Article 9 climate-branded funds present four times higher alignment with the EU taxonomy than the overall sample average, with 15% of revenues classified as green. Article 8 funds, however, have a similar alignment to the average, with 3.9% green revenues.
  • Funds focused on sectors that are doing heavy lifting in the green transition, such as utilities, show a higher exposure and alignment, with 25% green revenues.
  • Funds with equity themes, such as alternative energy, are naturally more aligned with a green economy, with up to 27% green revenues.

Patricia Pina, Head of Product Research & Innovation at Clarity AI, said: “Considering the disparate definitions of and frameworks for sustainability all around the world, we can look to the EU Taxonomy as a pioneer in setting a common standard to align a large segment of global market stakeholders. At Clarity AI, we believe regulation needs to be supported by detailed, data-led insights, and transparency cannot be a nice-to-have. It is a must-have.

“The EU recognizes that a key requirement to further the development of the sustainable investment market is ‘access to high-quality sustainability-related data.’ 2 This high-quality data also means moving away from subjectivity and using an objective and fact-based definition of what should be considered ‘green,’ ‘social,’ ‘environmental,’ and so on. The EU taxonomy gives us a common language that will enable stronger decision making and an acceleration to a more sustainable economy.

“Reliable, transparent insights are at the heart of fact-based sustainable finance. They should become the norm in making informed decisions around ‘green’ investing.”

Notes to editors

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors and organizations. As of December 2021, Clarity AI’s platform analyzes more than 30,000 companies, 180,000 funds, 198 countries and 187 local governments, and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in the US, Europe, and the Middle East. Clarity AI’s client network manages trillions in assets under management. clarity.ai

Methodology

Clarity AI developed a comprehensive assessment of how companies and funds align with the EU Taxonomy classification of sustainability using its proprietary sustainable analytics technology platform. Clarity AI draws on the broadest possible spectrum of tools and data sources available to increase the coverage, precision and objectivity of the sustainability analysis, while remaining transparent. The method in this paper relies on the three steps of Clarity AI's EU Taxonomy analysis and displays two key metrics that investors will need to report:

  • % Eligible green revenue: as defined by revenues exposed to the activities outlined in the EU Taxonomy
  • % Aligned green revenue: which builds upon eligible activities and embeds an assessment of the technical screening criteria, DNSH and SS requirements

Through its sustainability tech platform, Clarity AI can scalably assess >180,000 funds and >30,000 organizations. For this report, Clarity AI selected a subset of its universe where it takes a deeper look into the EU Taxonomy alignment for more than 31,000 funds globally. Clarity AI focused the analysis on the parent funds (independent of the asset classes) of equity-only funds for which it has enough characterization of the fund (e.g., assets under management, description, etc.). For the sake of comparison, they cover a broad range of regions, sectors and strategies.

1 As per the EU Taxonomy’s methodology of calculating alignment: Use the weighted average of the percent green revenues by company, which is based on the weights within a portfolio

2 As per the European Commission study published in June 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye